\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Prevention Fundamentals of Acute Coronary Syndromes in Uzbekistan},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2021 2021-03-15 (revised: 32 Year 2021 15 March 2021)}
\def\TheID{\makeatother }
\def\TheDate{2021 2021-03-15}
\title{Prevention Fundamentals of Acute Coronary Syndromes in Uzbekistan}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Ulugbek  Karimov}

             \author[2]{Nematjon  Mamasoliev}

             \author[3]{Laylo  Tajibaeva}

             \author[4]{Burkhonjon  Usmonov}

\renewcommand\Authands{ and }

\date{\small \em Received: 4 February 2021 Accepted: 4 March 2021 Published: 15 March 2021}

\maketitle


\begin{abstract}
        


Background: Cardiovascular disease (CVD) is the leading cause of death worldwide. An estimated 17.9 million people died from cardiovascular disease only in 2019, accounting for 32% of all deaths worldwide. Of these deaths, 85% were caused by heart attack and stroke. More than three quarters of deaths from cardiovascular disease occur in low-and middle-income countries.Methods: This research was conducted with the collaboration of Russian researchers RECORD-2 project (supervisor -Prof. N.A. Gratsiansky, coordinator -senior researcher A.D. Erlikh), patients age spectrum was between 26 to 88 years with a suspicion of one of the acute coronary syndromes at the time of admission to the hospital and included in the acute coronary syndrome register. A specially organized register included 612 patients with acute coronary syndrome.

\end{abstract}


\keywords{}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
he Cardiovascular Diseases (CVD) epidemic continues into the 21st century. For several decades, they have been the cause of death of the population in industrially developed countries, including the Commonwealth of Independent States (CIS), where, for example, almost 1.2 million people die from CVD every year in Russia, which is 55\% of the total mortality \hyperref[b0]{[1,}\hyperref[b1]{2,}\hyperref[b4]{5,}\hyperref[b8]{9,}\hyperref[b9]{10,}\hyperref[b10]{11]}. Moreover, the forecast for the future, especially for acute coronary syndrome (ACS), is not comforting. Therefore, for today, attention to the ACS is quite deserved. It is presented the epidemiological evidence obtained in different countries and populations of the world:\par
? There has been a decrease in mortality from CVD in the last 30 years in many economically developed countries, while in the CIS and Russia there is still a tendency towards an increase in mortality or CVD mortality rates, for example, in Russia, they are 2-4 times higher than in the USA, Canada and Australia \hyperref[b3]{[4,} {\ref 8,}\hyperref[b11]{12,}\hyperref[b12]{13}]; ? Mortality from ischemic heart disease (IHD) alone exceeds mortality from all types of neoplastic diseases combined \hyperref[b14]{[14,}\hyperref[b15]{15]}; ? At the age of 20 to 24 years, 8 people per 100 thousand of the population fall ill with IHD in some CIS countries, and at the age of 60 to 64 years, the numbers increase to 1712 per 100 thousand \hyperref[b2]{[3,}\hyperref[b5]{6,}\hyperref[b6]{7]}; ? A similar tense epidemiological situation takes place in almost all industrialized countries of the world \hyperref[b16]{[16,}\hyperref[b17]{17,} {\ref 18]}. It happens even though the clinical course of IHD/ACS is well known and many new drugs have been created that can affect the clinical manifestations of the disease. Consequently, there are still imperfections in clinical cardiology and, apparently, for a positive solution to these issues, it is necessary to give an evidence-based reorientation of the health care system to prevent and focus epidemiological research on the most common forms of CVD. An unequivocal scientific conclusion was made in modern research and it was proved that these approaches are reliable and with their help, key factors of the still-unidentified epidemiology of CVD can be determined not only when "... iceberg of diseases comes to the surface of clinical manifestations" (5-10\% of all cases), but also when "clinical manifestations are silent" \hyperref[b18]{[19,}\hyperref[b19]{20,}\hyperref[b20]{21,}\hyperref[b21]{22,}\hyperref[b22]{23]}.\par
This scientific problem is also especially relevant for Uzbekistan, since so far the ACS Registers have not been conducted in Uzbekistan and so far, naturally, there is no reliable opportunity to systematize knowledge about the current level of ACS treatment in various regional hospitals of the country. Thus, there could be, firstly, unfavourable epidemiological situations concerning ACS and, secondly, an unreliable idea of the quality of ACS treatment and its results in the conditions of Uzbekistan.\par
Based on the foregoing, the present work was conceived and carried out. The topic of the dissertation was chosen following the priority scientific research in the Republic of Uzbekistan related to early prevention and treatment of cardiovascular diseases, optimization of methods of prenosological diagnosis and pharmacotherapy.\par
The study aimed to determine the characteristics of prevalence, diagnosis, treatment and outcomes of ACS in modern conditions. 
\section[{II.}]{II.} 
\section[{Materials and Methods}]{Materials and Methods}\par
The work was carried out in the framework of the Russian RECORD-2 (supervisor -Prof. N.A. Gratsiansky, coordinator -senior researcher A.D. Erlikh), all consecutively hospitalized male and female patients aged 26 to 88 years with a suspicion of one of the acute coronary syndromes at the time of admission to the hospital and included in the ACS register. A specially organized register included 612 patients with ACS. 
\section[{III.}]{III.} 
\section[{Results and Discussion}]{Results and Discussion}\par
Men 414 (67.6\%) and women 198 (32.4\%). The average age of patients is 58.2 ± 11.3 years, minimum of 26 years and maximum of 88 years.\par
The results allowed us to identify 30 epidemiological, clinical, biochemical and pharmacoepidemiological Risk Factors associated with the development of ACS and their "endpoints" in the adult population of Andijan.\par
It has been proven that the chance of detecting ACS and "endpoints" in CVD patients is significantly higher in the presence of epidemiological (8), clinical \hyperref[b14]{(14)}, biochemical (4) and pharmacoepidemiological (4) factors than in their absence. Based on the obtained epidemiological, clinical and pharmacoepidemiological patterns of ACS development, a mathematical model of ACS was created and implemented for widespread use, which allows predicting the likelihood of ACS development and "endpoints" from them in patients with the indicated risk factors in almost 100.0\% of cases.\par
Further, based on the identified clinical and epidemiological features of the formation of ACS and the risk of "endpoints" from them, we have developed proposals for a model of urgent "life-saving prevention" of ACS in people with CVD in Andijan.\par
The chance of detecting ACS and "endpoints" in patients with CVD is significantly higher in the presence of epidemiological (8), clinical \hyperref[b14]{(14)}, biochemical (4) and pharmacoepidemiological (4) factors than in their absence. The frequency of identifying the noted risk factors or their combination, included in the presented mathematical model, makes it possible to predict the likelihood of developing ACS and "endpoints" from them in patients with these risk factors in almost 100.0\% of cases.\par
Based on the identified clinical and epidemiological features of the formation of ACS and the risk of "endpoints" from them, we have developed proposals for a model of urgent "life-saving prevention" of ACS in people with CVD in Andijan conditions (Table  {\ref 1}).\par
Table  {\ref 1}: Proposals for a model of urgent "salvage non-drug and drug prevention" of acute coronary syndromes and adverse events from them in CVD patients in Andijan conditions Objects of "aggressive" urgent "life-saving prevention" in patients with ACS Specificity of epidemiological risk factors and their impact on ACS\par
The direction of the strategy of primary, secondary and tertiary prevention Target -the basics of "life-saving prevention" Risks are male sex and age group> 65 years. In the formation of ACS and adverse events from them at the prehospital and hospital stages, as well as at discharge from the hospital, 30 risk factors are of priority importance. They should be the "main" guidelines for emergency prevention.\par
Preventive activities -drug and non-drug "aggressive" prophylaxis is carried out at the prehospital stage (by SVP / HHP, EMC), in the hospital (by narrow specialists, cardiologists) and at discharge (rehabilitation doctors, exercise therapy specialists, cardio dispensary doctors). Emergency prevention should be an obligatory component and coordinated process of treatment programs in all its stages. 
\section[{Continuation of table 1}]{Continuation of table 1}\par
Men and women under 50 Adverse epidemiological conditions concerning ACS are actively formed Groups for primary prevention are being formed by primary health care and primary prevention measures are being actively implemented Men and women -50-64 years old\par
The incidence of ACS is sharply increasing. The main risk factors of their development are all of the above factors, except for smoking and itching.\par
The introduction and implementation of special surveillance-epidemiological and preventive programs provide effective "life-saving prevention" against ACS 
\section[{Men and women> 65 years}]{Men and women> 65 years}\par
The main risk group for the development of ACS and "endpoints" from them. Relatively many very high-risk patients In health centers, in primary health care and the conditions of cardiac dispensaries, "aggressive" medication and nonmedication, continuous (lifelong) preventive interventions  
\section[{Conclusion}]{Conclusion}\par
As can be seen in Table  {\ref 1}, the model we developed entails the identification of target riskgenerating groups of the population/patients with CVD (target-basis for "life-saving prevention," men and women under 50 years old, men and women 50-64 years old, men and women > 65 years old, inadequate and incomplete "basic" pharmacotherapy in the standards of management of patients with ACS, inadequate and incomplete "basic" pharmacotherapy in the standards of management of patients with ACS).			\footnote{© 2021 Global JournalsPrevention Fundamentals of Acute Coronary Syndromes in Uzbekistan} 		 		\backmatter  			  				\begin{bibitemlist}{1}
\bibitem[ Writing Committee J Am Coll Cardiol ()]{b7}\label{b7} 	 		\textit{},  	 	 		\textit{Writing Committee J Am Coll Cardiol}  		2008. 51 p. .  	 
\bibitem[Vertkin and Emergency ()]{b2}\label{b2} 	 		\textit{A guide for doctors. -Moscow. -2007 [Skoraya meditsinskaya pomosh. Rukovodstvo dlya vrachey. -Moskva},  		 			A L Vertkin 		,  		 			Emergency 		.  		2007.  	 
\bibitem[Manson ()]{b18}\label{b18} 	 		‘Body weight and mortality among women’.  		 			J E Manson 		.  	 	 		\textit{N Engl J Med}  		1995. 333 p. .  	 
\bibitem[CAPRIE Streering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events // Lancet ()]{b14}\label{b14} 	 		\textit{CAPRIE Streering Committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events // Lancet},  		1996. 348 p. 1329.  	 
\bibitem[CAPTURE investigators: Randomised placebocontrolled trial of abciximab before and during coronary intervention in refractory unstable angina // //Lancet ()]{b15}\label{b15} 	 		\textit{CAPTURE investigators: Randomised placebocontrolled trial of abciximab before and during coronary intervention in refractory unstable angina // //Lancet},  		1997. 349 p. 1429.  	 
\bibitem[Diagnostics and treatment of patients with acute myocardial infarction with ST-segment elevation of the electrocardiogram. // Russian recommenddations. Committee of Experts of the All-Russian Scientific Society of Cardiology. -M. -2007. -66s [Diagnostika i lechenie bolnix ostrim infarktom miokarda s podemom segmenta ST elektrokardiogrammi. // Rossiyskiy rekomendatsii. Komitet ekspertov Vserossiyskogo nauchnogo obshestva kardiologov]{b3}\label{b3} 	 		\textit{Diagnostics and treatment of patients with acute myocardial infarction with ST-segment elevation of the electrocardiogram. // Russian recommenddations. Committee of Experts of the All-Russian Scientific Society of Cardiology. -M. -2007. -66s [Diagnostika i lechenie bolnix ostrim infarktom miokarda s podemom segmenta ST elektrokardiogrammi. // Rossiyskiy rekomendatsii. Komitet ekspertov Vserossiyskogo nauchnogo obshestva kardiologov},  		 	 	 (2007. -66s) 
\bibitem[Olsson and Schwartz ()]{b22}\label{b22} 	 		\textit{Early initiation of treatment with statins in acute coronary syndromes},  		 			A G Olsson 		,  		 			G G Schwartz 		.  		2002. 34 p. .  	 
\bibitem[Yavelov ()]{b6}\label{b6} 	 		‘Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. American College of Cardiology/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the Canadian Cardiovascular Society Endorsed by the American Academy of Family Physicians’.  		 			I S Yavelov 		.  	 	 		\textit{Yavelov I.S}  		2005. 2005. 2007. 2007. 2004. 7 p. .  	 	 (Primenenie beta-adrenoblokatorov pri serdechno-sosudistix zabolevaniyax: sovremennie rekomendatsii. //Cons Med. Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the) 
\bibitem[Matriniuk et al. ()]{b19}\label{b19} 	 		\textit{For the Asia-Pacific Cohort Studies Collaboration. The fraction of ischaemic heart disease and stroke attributable to smoking in the WHO Western Pacific and South-East Asian regions. //Tob Control},  		 			A L C Matriniuk 		,  		 			C M Y Lee 		,  		 			T H Lam 		,  		 			R Huxley 		,  		 			I Suh 		,  		 			K Jamrozik 		,  		 			D F Gu 		,  		 			M Woodward 		.  		2006. 15 p. .  	 
\bibitem[???/??? ()]{b12}\label{b12} 	 		\textit{Guidelines for the Management of Patients With Acute Myocardial Infarction},  		 			???/??? 		.  		1999.  	 
\bibitem[Acc/Aha ()]{b10}\label{b10} 	 		\textit{Guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction. A report of the American College of Cardiology /American Heart Association Task force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non-st-elevation myocardial infarction). //Circulation},  		 			Acc/Aha 		.  		2007. 2007. 116 p. .  	 
\bibitem[Acc/Aha ()]{b9}\label{b9} 	 		\textit{Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). //J Am Coll Cardiol},  		 			Acc/Aha 		.  		2007. 2007. 50 p. .  	 
\bibitem[Acc/Aha ()]{b8}\label{b8} 	 		\textit{Guidelines Update for the Management of Patients with Chronic Stable Angina -summary article. A Report of ACC/AHA Task Force on Practice Guidelines // Circulation},  		 			Acc/Aha 		.  		2002. 2003. 107 p. .  	 
\bibitem[Acc/Aha ()]{b11}\label{b11} 	 		\textit{Guidelines Update for the Management of Patients with Unstable Angina and non-ST segment Elevation Myocardial Infarction: a Report of the American College of Cardiology/ American Heart Association Task Forse on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) // Circulation},  		 			Acc/Aha 		.  		2002. 106 p. .  	 
\bibitem[Morrison et al. ()]{b21}\label{b21} 	 		\textit{Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis},  		 			L J Morrison 		,  		 			P R Verbeek 		,  		 			A C Mcdonald 		,  		 			B V Sawadsky 		,  		 			D J Cook 		.  		2000. 283 p. .  	 
\bibitem[Staroverov]{b5}\label{b5} 	 		‘Myocardial infarction: new perspectives of fibrinolytic therapy" // Doctor. RU’.  		 			I I Staroverov 		.  	 	 		\textit{Staroverov I.I}  		 (4)  p. .  	 	 (Infarkt miokarda: novie perspektivi fibrinoliticheskoy terapii //Doktor. Ru. -2004. -?4. -S.52-53.) 
\bibitem[Bokarev et al. (ed.) ()]{b1}\label{b1} 	 		\textit{Ostry koronarniy sindrom i yego lechenie // Uchebnoe posobie},  		 			I N Bokarev 		,  		 			M B Aksenova 		,  		 			T Khlevchuk 		.  		 2009. - s.170.  		Bokarev I.N., ?ksenova M.B., Xlevchuk T.V. (ed.)  		2009. p. 170.  	 	 (Acute coronary syndrome and its treatment // Textbook) 
\bibitem[Krolewski et al. (ed.) ()]{b17}\label{b17} 	 		\textit{Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association},  		 			A S Krolewski 		,  		 			J H Warram 		,  		 			P Valsania 		.  		56S-61S. 18. Lansky A.J., Hochman J.S., Ward P.A. (ed.)  		1991. 2005. 90 p. .  	 	 (Evolving natural history of coronary artery disease in diabetes mellitus) 
\bibitem[Folland et al. ()]{b16}\label{b16} 	 		\textit{Percutaneous transluminal coronary angioplasty (PTCA) compared to medical therapy for stable angina pectoris: outcomes for patients with double vessel compared to single vessel coronary artery disease in randomized VA cooperative study},  		 			E D Folland 		,  		 			P M Hartigan 		,  		 			A F Parisi 		.  		1997. 29 p. .  	 
\bibitem[Mokdad et al. (2001)]{b20}\label{b20} 	 		‘Prevalence of obesity, diabetes, and obesity-related health risk factors’.  		 			A H Mokdad 		,  		 			E S Ford 		,  		 			B A Bowman 		,  		 			W H Dietz 		,  		 			F Vinicor 		,  		 			V S Bales 		,  		 			J Marks 		.  	 	 		\textit{JAMA}  		2001. Jan 1. 2003. 289  (1)  p. .  	 
\bibitem[Lange et al.]{b4}\label{b4} 	 		\textit{Reperfuzionnaya terapiya pri ostrom infarkte miokarda // Mejdunarodniy Med},  		 			R Lange 		,  		 			R Hillis D ; Lange 		,  		 			D Xillis 		.  		p. .  	 	 (Reperfusion therapy in acute myocardial infarction" // International Med. ? 6. -S. 28-33.) 
\bibitem[Uptate]{b13}\label{b13} 	 		\textit{Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)},  		 			Uptate 		.  		 	 	 (Web version) 
\bibitem[Aronov ()]{b0}\label{b0} 	 		‘Treatment of atherosclerosis and prevention’.  		 			D Aronov 		.  	 	 		\textit{Triada X, 2000. [?ronov D. M. Lechenie ateroskleroza i profilaktika. -M.: Triada X},  				2000.  	 
\end{bibitemlist}
 			 		 	 
\end{document}
